Abstract:Abstract Background and Aims Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and some glucagon-like-1 receptor agonists (GLP1-RA) have demonstrated to delay diabetic nephropathy (DN) progression. Potentially, the combination of these two therapeutic approaches on top of the standard of care with renin angiotensin system (RAS) blockers could exert additive cardiorenal protection in the diabetic milieu. The present study aimed to evaluate the cardiorenal protective effects of the combination of SGLT2i and GLP1-RA on top of RAS blockade versus the monotherapies on top of RAS blockade in experimental diabetes. Method Twelve weeks old male and female uninefrectomized (UNx) db/db mice were treated for 8 weeks with an SGLT2i (empagliflozin, 10 mg/Kg/day five days a week) and/or a GLP1-RA (semaglutide, 10.0 nmol/kg twice per week) on top of a RAS blocker (ramipril, 8 mg/Kg/day). Vehicle-treated UNx db/db and non-diabetic (db/m) mice were included as controls. During the experiment weight, food and water intake, blood glucose, blood pressure (BP) and glomerular filtration rate (GFR) were measured. Kidney and heart were collected at the end of the experiment. Results The vehicle-treated UNx db/db showed increased body weight, food and water intake and blood glucose as compared to the vehicle-treated UNx db/m (Fig. 1A, B and C, p = 0.03, p<0.001 and p<0.0001, respectively). The GFR slope (ΔGFR, difference between final and basal GFR) was also significantly higher in the vehicle-treated UNx db/db vs the vehicle-treated UNx db/m (Fig. 1D, p = 0.02), a typical feature of incipient DN. All treatments significantly decreased systolic and diastolic BP as compared to vehicle-treated UNx db/db due to its ramipril component (Fig. 1E). Further, both empagliflozin and semaglutide (alone or combined) on top of ramipril lowered blood glucose in UNx db/db (Fig. 1C, p<0.001 vs vehicle UNx db/db in all cases) but semaglutide component maximized this effect. Food and water intake was decreased in UNx db/db treated with semaglutide on top of RAS blockade (alone or combined with empagliflozin) as compared to vehicle-treated UNx db/db (Fig. 1B) although no differences in body weight were noted between treated and untreated UNx db/db (Fig. 1A). A trend towards ΔGFR decline was observed in UNx db/db treated with empagliflozin and semaglutide on top of RAS blockade (Fig. 1D). Finally, heart weight but not kidney weight was significantly lower in all treated UNx db/db as compared to vehicle-treated UNx db/db (Fig. 1F). Conclusion Our preliminary results show that addition of semaglutide to empagliflozin therapy on top of RAS blockade could have synergic hypoglycemic effects. Further, although more research is needed, both empagliflozin and semaglutide in combination with ramipril trended to ameliorate diabetic hyperfiltration and decreased heart weight in a DN mouse model which suggests cardiorenal beneficial effects.

The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes

The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy

Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long‐acting dual amylin and calcitonin receptor agonist improves insulin‐mediated glycaemic control and controls body weight

The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy

Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss

DACRA induces profound weight loss, satiety control, and increased mitochondrial respiratory capacity in adipose tissue

A r andomis e d, controlled, double blind s tudy to assess mechan i stic effects of combination therapy of dapag li flozin with e xenatide QW versus dapagliflozin alone i n obese patients with t ype 2 diabetes mellitus (RESILIENT): study protocol

#4581 EVALUATION OF THE BENEFICIAL EFFECTS OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONIST ON TOP OF RAS BLOCKADE IN EXPERIMENTAL DIABETIC NEPHROPATHY

213-OR: Antidiabetic Potential of Novel, Long-Acting Amylin Analogue ZP8396 in ZDF Rats

Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus

Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes

The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs

Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial

Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes

Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy

Long-Term Effectiveness of Quadruple Combination Therapy with Empagliflozin Versus Basal Long-Acting Insulin Therapy in Patients with Type 2 Diabetes: 3-Year Retrospective Observational Study

Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide

Long-Term Activation of Glucagon-like peptide-1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes

Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes